Hybio Pharmaceutical Co., Ltd.
300199
Rang in aandelen
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Aandeelprijs
$3.69
Marktkapitalisatie
$3.11B
Verandering (1 dag)
-7.75%
Verandering (1 jaar)
21.56%
Land
CN
Handel Hybio Pharmaceutical Co., Ltd. (300199)
Categorie
Healthcare
P/B-ratio voor Hybio Pharmaceutical Co., Ltd. (300199)
P/B-ratio op October 2026 TTM: 25.60
Volgens de meest recente financiële rapporten en aandelenkoers van Hybio Pharmaceutical Co., Ltd. is de huidige P/B-ratio (TTM) 25.60. Eind 2024 had het bedrijf een P/B-ratio van 19.34.
P/B-ratiohistoriek voor Hybio Pharmaceutical Co., Ltd. van 2007 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 25.60 | -3.99% |
| 2025 | 26.66 | 37.81% |
| 2024 | 19.34 | 23.26% |
| 2023 | 15.69 | 28.42% |
| 2022 | 12.22 | 73.87% |
| 2021 | 7.03 | 95.95% |
| 2020 | 3.59 | 56.01% |
| 2019 | 2.30 | -4.08% |
| 2018 | 2.40 | -38.83% |
| 2017 | 3.92 | -11.20% |
| 2016 | 4.41 | -47.39% |
| 2015 | 8.39 | -10.82% |
| 2014 | 9.40 | 22.83% |
| 2013 | 7.66 | 176.43% |
| 2012 | 2.77 | -23.56% |
| 2011 | 3.62 | -70.42% |
| 2010 | 12.25 | -27.52% |
| 2009 | 16.90 | -2.01% |
| 2008 | 17.25 | -50.92% |
| 2007 | 35.14 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 1.9834 | -92.25% |
DE
|
|
| 2.1139 | -91.74% |
DE
|
|
| 1.3124 | -94.87% |
JP
|
|
| 6.3468 | -75.20% |
CH
|
|
| 5.0287 | -80.35% |
IN
|
